VC & Startups/Nov 20 edition/Reporting & analysis
FundingVenture funds

FundingRounds, leads & terms

Boltz raises $110M Series A led by Bessemer for AI biomolecular design

Boltz grew out of an MIT team that released its biomolecular models openly. It has raised a $110 million Series A led by Bessemer Venture Partners, and Andreessen Horowitz has also invested, as pharmaceutical companies make more use of its drug-design AI.

From the a16z article of November 18, 2026 and cited sources: Boltz closed a $110 million Series A led by Bessemer Venture Partners to bring AI-powered biomolecular design to scientists more broadly. [1] [2] [3] [4]

SOURCES[1] Investing in Boltz a16z.news[2] Boltz Raises $110M Series A Led by Bessemer for… aiweekly.co[3] London-based Boltz raises $110M Series A - Tech.eu tech.eu

AI-assisted, not human-edited. Methodology Corrections Who owns this site

KEY FACTS
What happened
Boltz closed a $110 million Series A led by Bessemer Venture Partners to bring AI-powered biomolecular design to scientists more broadly. [1] [2] [3] [4] [7] [9]
Original source
a16z article, independent perspective
Brief by
AT Pulse research desk AI-assisted; publisher and contact on the desk page
When
November 18, 2026 article published
Evidence
13 sources across 13 sites
28/100RisingHow it’s measured

Substack · 2 likes · 1 comment

Reach blends public engagement (views, likes, comments, shares, stars) from the platforms where the story or its original source lives: YouTube, Hacker News, GitHub, Substack and similar. A video and the article written from its transcript share one score, taken from the video. Platforms with no data are left out rather than counted as zero, and the age of a story never lowers its score.

Illustration from a16z: Boltz raises $110M Series A led by Bessemer for AI biomolecular design
Image: a16z — Original article ↗
THE CORE IDEAS3 TAKEAWAYS
01

Boltz closed a $110 million Series A led by Bessemer Venture Partners to bring AI-powered biomolecular design to scientists more broadly. Andreessen Horowitz has published its own investment announcement. [1] [2] [3] [4] [7] [9]

02

Boltz says six of the world's 20 largest pharmaceutical companies are partners. Trade coverage ties the raise to a roughly 50-fold rise in use of its AI models. [5] [6]

03

The team gave its models away openly. It now earns money by charging pharmaceutical customers for usage, metered per token, instead of selling licences to the models. [10]

WHY IT MATTERS

The evidence is a large Series A and reported uptake among big pharma companies. One implication is that open-source scientific models can lead to paid, usage-based enterprise revenue, but this case does not prove the model works in general.

The rest of the dossier was stopped by a safety filter before it finished. That cut the Claims and evidence section partway through and left out the last four sections and the Sources list.

The executive brief, timeline, capabilities and technical sections went through intact.

FOLLOW THE EVIDENCE

The source trail.

Sources (13)
A LITTLE LESS NOISE. A LOT MORE CONTEXT.

Stay curious.
Follow the evidence.

Independent perspectives, the original sources, and room for the questions that don't have easy answers.

How we build the brief
Connect with us

Find us where you already read.